FDA Panel Supports Pfizer's Low-Dose Covid-19 Vaccine For Kids Ages 5-11
On Tuesday, a Food and Drug Administration advisory panel voted that the benefits of Pfizer's low-dose Covid-19 vaccine for kids ages 5-11 far outweigh the potential risks.
Last Friday, Pfizer released a study showing that their Covid-19 vaccine proved to be nearly 91% effective at preventing symptomatic infections in kids ages 5-11.
If regulators approve the vaccine, the rollout could begin as soon as early November.
Pfizer requested vaccine authorization for this age group a few weeks back. The FDA and CDC are expected to make a final decision next week.
Pfizer tested smaller doses in the young children, a third of what's normally given to adults and teens. The trials proved to be effective with the young children developing antibodies against Covid-19 and having minimal side effects.
Photo Source: WIX Media